Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Allain

Showing results (21-30 of 187) with videos related to

Pageof 19
Sort By:
Therapie|May 1, 1993
[The elderly healthy volunteer: a necessity]H Allain, F Le Coz, M Bureau
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1993
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter TrialH Allain, P Pollak, H C Neukirch
Acta Neurologica Scandinavica. Supplementum|January 1, 1991
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT)H Allain, J Cougnard, H C Neukirch
Clinical Therapeutics|July 1, 1990
Choosing a target for cognitive enhancersH Allain, D Bentué-Ferrer, R Decombe
L'Encephale|November 1, 2001
[Acting out and psychoactive substances: alcohol, drugs, illicit substances]C Gillet, E Polard, N Mauduit, et al.
Nature Structural Biology|March 13, 1999
Solution structure of the loop B domain from the hairpin ribozymeS E Butcher, F H Allain, J Feigon
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 monthsP Lemoine, H Allain, C Janus, et al.
Therapie|March 21, 1998
[Role of clinical trials in memory clinics]H Allain, V Baudoin, B Dubois, et al.
Presse Medicale (Paris, France : 1983)|May 4, 1985
[Dysphagia in Parkinson's disease]H Allain, A Gosselin, D Milon, et al.
Presse Medicale (Paris, France : 1983)|March 26, 1988
[Myoclonic encephalopathy probably attributable to propafenone]M Madigand, J Dien, G Pavin, et al.
Pageof 19

Showing results (21-30 of 187) with videos related to

Sort By:
Pageof 19
Therapie|May 1, 1993
[The elderly healthy volunteer: a necessity]H Allain, F Le Coz, M Bureau
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1993
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter TrialH Allain, P Pollak, H C Neukirch
Acta Neurologica Scandinavica. Supplementum|January 1, 1991
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT)H Allain, J Cougnard, H C Neukirch
Clinical Therapeutics|July 1, 1990
Choosing a target for cognitive enhancersH Allain, D Bentué-Ferrer, R Decombe
L'Encephale|November 1, 2001
[Acting out and psychoactive substances: alcohol, drugs, illicit substances]C Gillet, E Polard, N Mauduit, et al.
Nature Structural Biology|March 13, 1999
Solution structure of the loop B domain from the hairpin ribozymeS E Butcher, F H Allain, J Feigon
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 monthsP Lemoine, H Allain, C Janus, et al.
Therapie|March 21, 1998
[Role of clinical trials in memory clinics]H Allain, V Baudoin, B Dubois, et al.
Presse Medicale (Paris, France : 1983)|May 4, 1985
[Dysphagia in Parkinson's disease]H Allain, A Gosselin, D Milon, et al.
Presse Medicale (Paris, France : 1983)|March 26, 1988
[Myoclonic encephalopathy probably attributable to propafenone]M Madigand, J Dien, G Pavin, et al.
Pageof 19